TY - JOUR
T1 - Improving phage therapy by evasion of phage resistance mechanisms
AU - Bleriot, Inés
AU - Pacios, Olga
AU - Blasco, Lucia
AU - Fernández-García, Laura
AU - López, María
AU - Ortiz-Cartagena, Concha
AU - Barrio-Pujante, Antonio
AU - García-Contreras, Rodolfo
AU - Pirnay, Jean Paul
AU - Wood, Thomas K.
AU - Tomás, María
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - Antibiotic failure is one of the most worrisome threats to global health. Among the new therapeutic efforts that are being explored, the use of bacteriophages (viruses that kill bacteria), also known as ‘phages’, is being extensively studied as a strategy to target bacterial pathogens. However, one of the main drawbacks of phage therapy is the plethora of defence mechanisms that bacteria use to defend themselves against phages. This review aims to summarize the therapeutic approaches that are being evaluated to overcome the bacterial defence systems, including the most innovative therapeutic approaches applied: circumvention of phage receptor mutations; modification of prophages; targeting of CRISPR-Cas systems and the biofilm matrix; engineering of safer and more efficacious phages; and inhibition of the anti-persister strategies used by bacteria.
AB - Antibiotic failure is one of the most worrisome threats to global health. Among the new therapeutic efforts that are being explored, the use of bacteriophages (viruses that kill bacteria), also known as ‘phages’, is being extensively studied as a strategy to target bacterial pathogens. However, one of the main drawbacks of phage therapy is the plethora of defence mechanisms that bacteria use to defend themselves against phages. This review aims to summarize the therapeutic approaches that are being evaluated to overcome the bacterial defence systems, including the most innovative therapeutic approaches applied: circumvention of phage receptor mutations; modification of prophages; targeting of CRISPR-Cas systems and the biofilm matrix; engineering of safer and more efficacious phages; and inhibition of the anti-persister strategies used by bacteria.
UR - http://www.scopus.com/inward/record.url?scp=85184828134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184828134&partnerID=8YFLogxK
U2 - 10.1093/jacamr/dlae017
DO - 10.1093/jacamr/dlae017
M3 - Review article
C2 - 38343627
AN - SCOPUS:85184828134
SN - 2632-1823
VL - 6
JO - JAC-Antimicrobial Resistance
JF - JAC-Antimicrobial Resistance
IS - 1
M1 - dlae017
ER -